Virios Therapeutics, Inc.

  • About Virios
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Corporate Presentation
  • Target Diseases
    • Fibromyalgia
    • Long Covid
    • Blog
  • Pipeline
    • Pipeline
    • Presentations and Publications
  • Investors
  • News
  • Contact

Presentations

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • Events & Presentations

  • Events
  • Presentations
  • Shareholder Letters
  • Meeting
Q4 2022 Corporate Presentation
Dec 14, 2022

Q4 2022 Corporate Presentation

FORTRESS Study Summary
Sep 19, 2022

FORTRESS Study Summary

International Association for the Study of Pain (IASP) World Congress 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – The Safety of IMC‑1 in Patients With Fibromyalgia: Phase 2a Study Results

International Association for the Study of Pain (IASP) World Congress 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – The Safety of IMC‑1 in Patients With Fibromyalgia: Phase 2a Study Results

EULAR European Congress of Rheumatology 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – IMC‑1, a Fixed Dose Combination of Famciclovir and Celecoxib, Improves Common Symptoms Associated With Fibromyalgia in Addition to Pain: Post Hoc Analysis of a Phase 2a Trial

EULAR European Congress of Rheumatology 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – IMC‑1, a Fixed Dose Combination of Famciclovir and Celecoxib, Improves Common Symptoms Associated With Fibromyalgia in Addition to Pain: Post Hoc Analysis of a Phase 2a Trial

Digestive Disease Week® (DDW) 2021 Presentation – Carol Duffy, PhD; William Pridgen, MD – Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study

Digestive Disease Week® (DDW) 2021 Presentation – Carol Duffy, PhD; William Pridgen, MD – Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study

Journal of Pain Research – William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – A Famciclovir + Celecoxib Combination Treatment is Safe and Efficacious in the Treatment of Fibromyalgia

RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2023 Virios Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines